Annual financial results as of 31 December, 2020
30/04/2021 – AB Science reports its annual financial results as of 31 December, 2020
Masitinib Phase 2B/3 study in prostate cancer met its primary endpoint
29/04/2021 – AB Science today announces that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government
14/04/2021 – AB Science today announces that it has received financing approval from Société Générale, Bpifrance and Banque Populaire for a total of EUR 6 million in the form of state-guaranteed loans
Signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
06/04/2021 – AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19